<DOC>
	<DOCNO>NCT00795145</DOCNO>
	<brief_summary>The FDA ask Pfizer ass risk linezolid QT interval ( obtain ECG reading ) could predispose patient ventricular arrhythmias . This study conduct satisfy requirement .</brief_summary>
	<brief_title>A Study To Assess The Effect Of Linezolid On QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male female subject age 21 55 year . Body mass Index ( BMI ) 18 30 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . An informed consent document sign date . Evidence history clinically significant abnormality . 12lead ECG demonstrate QTc &gt; 450 msec Screening . Receiving selective serotonin reuptake inhibitor ( SSRIs ) and/or sympathomimetic agent . Abnormal liver function test . A positive urine drug screen , history excessive alcohol tobacco use .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Linezolid , QTc interval , pharmacokinetics , therapeutic dose , supra-therapeutic dose</keyword>
</DOC>